(Meropenem + vaborbactam) is under clinical development by Melinta Therapeutics and currently in Phase I for Bacterial Infections. According to GlobalData, Phase I drugs for Bacterial Infections have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Meropenem + vaborbactam)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Meropenem + vaborbactam) overview
Meropenem and vaborbactam (Vabomere, Vaborem) is a fixed dose combination drug, acts as antibacterial agent and anti infective agent. It is formulated as powder for solution for intravenous route of administration. Vabomere is indicated for the treatment of complicated urinary tract infections (cUTI), including a type of kidney infection includes pyelonephritis caused by specific bacteria in adult patients.
Meropenem (RPX2014) in combination with vaborbactam (RPX7009) is under development for the treatment of pyelonephritis and gram-negative bacterial infections including carbapenam resistant Enterobacteriaceae infections, complicated urinary tract infections (cUTI), bacteremia, complicated intra-abdominal infection, Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonias (VABP). It was also under development for the treatment of renal insufficiency and hospital-acquired pneumonia, ventilator associated pneumonia.
Melinta Therapeutics overview
Melinta Therapeutics, LLC (Melinta) is a biopharmaceutical company that focuses on the development of novel anti-infectives for the treatment of various bacterial infections. Its marketed portfolio encompasses antibiotics for the treatment of serious bacterial infections including acute bacterial skin and skin structure infections (ABSSSI), complicated urinary tract infections (cUTI), and for the prevention and treatment of other serious infections that are caused by susceptible bacteria. The company is also evaluating delafloxacin for the treatment of serious community-acquired bacterial pneumonia (CABP), meropenem and vaborbactam, oritavancin, and minocycline. Melinta’s products and pipeline candidates are built on a ribosome platform licensed from Yale University. Melinta is headquartered in Parsippany, New Jersey, the US.
For a complete picture of (Meropenem + vaborbactam)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
